{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:10:25Z","timestamp":1772082625083,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41433-025-04063-y","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:47:56Z","timestamp":1760046476000},"page":"3278-3283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Conjunctival histopathological changes associated with netarsudil 0.02%"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8066-9278","authenticated-orcid":false,"given":"Michelle T.","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaow","family":"Charoenkijkajorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-6941","authenticated-orcid":false,"given":"Jonathan H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald S.","family":"Minckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuldev","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"4063_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"4063_CR2","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1167\/iovs.05-1617","volume":"48","author":"H Tokushige","year":"2007","unstructured":"Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Investig Ophthalmol Vis Sci. 2007;48:3216\u201322.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4063_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","volume":"24","author":"RF Wang","year":"2015","unstructured":"Wang RF, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24:51\u201354.","journal-title":"J Glaucoma"},{"key":"4063_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","volume":"158","author":"PV Rao","year":"2017","unstructured":"Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho GTPase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research. Exp Eye Res. 2017;158:23\u201332.","journal-title":"Exp Eye Res"},{"key":"4063_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1089\/jop.2017.0138","volume":"34","author":"A Kazemi","year":"2018","unstructured":"Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharm Ther. 2018;34:380\u20136.","journal-title":"J Ocul Pharm Ther"},{"key":"4063_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2646904","volume":"2017","author":"N Okumura","year":"2017","unstructured":"Okumura N, Kinoshita S, Koizumi N. Application of Rho kinase inhibitors for the treatment of corneal endothelial diseases. J Ophthalmol. 2017;2017:2646904.","journal-title":"J Ophthalmol"},{"key":"4063_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1089\/jop.2022.0069","volume":"38","author":"RL Lindstrom","year":"2022","unstructured":"Lindstrom RL, Lewis AE, Holland EJ, Sheppard JD, Hovanesian JA, Senchyna M, et al. Phase 2, randomized, open-label parallel-group study of two dosing regimens of netarsudil for the treatment of corneal edema due to Fuchs corneal dystrophy. J Ocul Pharm Ther. 2022;38:657\u201363.","journal-title":"J Ocul Pharm Ther"},{"key":"4063_CR8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2147\/OPTH.S216907","volume":"14","author":"S Kusuhara","year":"2020","unstructured":"Kusuhara S, Nakamura M. Ripasudil hydrochloride hydrate in the treatment of glaucoma: safety, efficacy, and patient selection. Clin Ophthalmol. 2020;14:1229\u201336.","journal-title":"Clin Ophthalmol"},{"key":"4063_CR9","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","volume":"29","author":"IP Singh","year":"2020","unstructured":"Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, et al. Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2020;29:878\u201384.","journal-title":"J Glaucoma"},{"key":"4063_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/archopht.123.2.166","volume":"123","author":"BA Francis","year":"2005","unstructured":"Francis BA, Du LT, Najafi K, Murthy R, Kurumety U, Rao N, et al. Histopathologic features of conjunctival filtering blebs. Arch Ophthalmol. 2005;123:166\u201370.","journal-title":"Arch Ophthalmol"},{"key":"4063_CR11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/bjo.77.9.590","volume":"77","author":"D Broadway","year":"1993","unstructured":"Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol. 1993;77:590\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4063_CR12","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/archopht.1994.01090230051020","volume":"112","author":"DC Broadway","year":"1994","unstructured":"Broadway DC, Grierson I, O\u2019Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437\u201345.","journal-title":"Arch Ophthalmol"},{"key":"4063_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0161-6420(89)32888-0","volume":"96","author":"MB Sherwood","year":"1989","unstructured":"Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon\u2019s capsule in glaucomatous patients. Ophthalmology. 1989;96:327\u201335.","journal-title":"Ophthalmology"},{"key":"4063_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00061198-200106000-00017","volume":"10","author":"DC Broadway","year":"2001","unstructured":"Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001;10:237\u201349.","journal-title":"J Glaucoma"},{"key":"4063_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0161-6420(94)31322-4","volume":"101","author":"C Baudouin","year":"1994","unstructured":"Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994;101:454\u201360.","journal-title":"Ophthalmology"},{"key":"4063_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1442-9071.2003.00760.x","volume":"32","author":"AS Dogan","year":"2004","unstructured":"Dogan AS, Orhan M, Soylemezoglu F, Irkec M, Bozkurt B. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Exp Ophthalmol. 2004;32:62\u201366.","journal-title":"Clin Exp Ophthalmol"},{"key":"4063_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/vop.12734","volume":"24","author":"KA Leary","year":"2021","unstructured":"Leary KA, Lin KT, Steibel JP, Harman CD, Komaromy AM. Safety and efficacy of topically administered netarsudil (Rhopressa) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG). Vet Ophthalmol. 2021;24:75\u201386.","journal-title":"Vet Ophthalmol"},{"key":"4063_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1517\/14728222.9.4.715","volume":"9","author":"E Hu","year":"2005","unstructured":"Hu E, Lee D. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin Ther Targets. 2005;9:715\u201336.","journal-title":"Expert Opin Ther Targets"},{"key":"4063_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0008-4182(02)80094-1","volume":"37","author":"P Blondeau","year":"2002","unstructured":"Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002;37:21\u201326.","journal-title":"Can J Ophthalmol"},{"key":"4063_CR20","doi-asserted-by":"publisher","first-page":"e26724","DOI":"10.1097\/MD.0000000000026724","volume":"100","author":"PH Yeh","year":"2021","unstructured":"Yeh PH, Cheng YC, Shie SS, Lee YS, Shen SC, Chen HS, et al. Brimonidine related acute follicular conjunctivitis: onset time and clinical presentations, a long-term follow-up. Medicine. 2021;100:e26724.","journal-title":"Medicine"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04063-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:39:16Z","timestamp":1764599956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04063-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":20,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4063"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04063-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}